Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Bod Australia signs deal to produce hemp-based mānuka honey

ASX-listed Bod Australia signs deal to produce hemp-based mānuka honey

By Sophie Boot

Jan. 18 (BusinessDesk) - ASX-listed Bod Australia has signed an agreement with mānuka honey producer Manuka Pharma to produce a hemp-based honey product line.

Bod, a developer and distributor of cosmetics and natural medicines, is aiming to develop a range of over-the-counter and therapeutic products using cannabis extracts. It says it's building a sustainable, multi-faceted cannabis business through a deal with Swiss manufacturer Linnea Natural Pharma Solutions. The honey agreement will see Manuka Pharma source, develop and manufacture the product, with Bod then importing the honey to Australia and packaging it for sale.

While Bod describes Manuka Pharma as a New Zealand-based company, it is not registered with the New Zealand Companies' Office, and its registration with the Australian Business Register says its main business location is Belrose, New South Wales. Manuka Pharma's website, which has an Australian domain name, links the company to three brands: Australian BeeBio, Wairarapa-based Watson & Son, and ManukaMed, a company which sells wound care in the USA but whose New Zealand Companies Office registration ceased in October last year after the company was placed into liquidation.

The honey will be sold in pharmacies in Australia, and Bod also plans to target health food and supplement stores, as well as Asian markets such as China. The product will give consumers "a source of high-quality protein and essential fatty acids from the addition of hemp seeds, as well as the added health benefits of a high-grade, high methylglyoxal (MGS) manuka honey", Bod said.

Late last year, the government announced a new labelling standard for mānuka honey, set to come into force from Feb. 5, after much industry concern that non-mānuka honey was being misleadingly sold as such. The honey will be tested for four chemical markers and one DNA marker before being sold overseas as mānuka. The UK Trademark Registry has also approved New Zealand's registration of the mānuka honey name, something which the Australian Manuka Honey Association has said it will oppose.

Mānuka honey is worth $180 million to New Zealand every year, and in its statement to the ASX Bod cited a January 2016 report that global import demand for Kiwi honey was estimated to be worth about US$2.1 billion. At the time, ANZ Bank New Zealand rural economist Con Williams said the largest growth opportunities for New Zealand exporters were wealthier countries who are high consumers of honey where New Zealand has low penetration such as the US, Germany, France and other European countries such as Belgium, the Netherlands and Switzerland.

While the high volume markets tend to pay US$21-US$28 a kilogram, higher value markets will pay US$30-US$50/kg and medical grade mānuka can fetch up to $1,000/kg, Williams said.

Bod's ASX-listed shares rose 4.2 percent to 62 Australian cents.

(BusinessDesk)

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Industry Report: Growing Interactive Sector Wants Screen Grants

Introducing a coordinated plan that invests in emerging talent and allows interactive media to access existing screen industry programmes would create hundreds of hi-tech and creative industry jobs. More>>

ALSO:

Ground Rules: Government Moves To Protect Best Growing Land

“Continuing to grow food in the volumes and quality we have come to expect depends on the availability of land and the quality of the soil. Once productive land is built on, we can’t use it for food production, which is why we need to act now.” More>>

ALSO:

Royal Society: Calls For Overhaul Of Gene-Technology Regulations

An expert panel considering the implications of new technologies that allow much more controlled and precise ‘editing’ of genes, has concluded it’s time for an overhaul of the regulations and that there’s an urgent need for wide discussion and debate about gene editing... More>>

ALSO:

Retail: Card Spending Dips In July

Seasonally-adjusted electronic card spending dipped in July by 0.1 percent after being flat in June, according to Stats NZ. Economists had expected a 0.5 percent lift, according to the median in a Bloomberg poll. More>>

ALSO:

Product Stewardship: Govt Takes More Action To Reduce Waste

The Government is proposing a new way to deal with environmentally harmful products before they become waste, including plastic packing and bottles, as part of a wider plan to reduce the amount of rubbish ending up in landfills. More>>

ALSO:

Earnings Update: Fonterra Sees Up To $675m Loss On Writedowns

“While the Co-op’s FY19 underlying earnings range is within the current guidance of 10-15 cents per share, when you take into consideration these likely write-downs, we expect to make a reported loss of $590-675 million this year, which is a 37 to 42 cent loss per share." More>>

ALSO: